1 completed, 1 withdrawn. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow CD14152 placebo: new trials by email Literature Review of CD14152 placebo trials Research Report on CD14152 placebo
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable Nemolizumab, CD14152 placebo - Moderate-to-severe Atopic Dermatitis | Phase 3 | Withdrawn | Galderma R&D | 2023-01-01 | 2023-09-21 | |
| Safety and Efficacy of Nemolizumab in PN CD14152 Dose A, CD14152 placebo - Prurigo Nodularis | Phase 2 | Completed | Galderma R&D | 70 | 2017-10-02 | 2020-02-19 |
Galderma R&D (2)
Austria (1) · France (1) · Germany (1) · Poland (1)